Two Chemotherapy Regimens Plus or Minus Bevacizumab
Compare the effect of capecitabine (cape) + temozolomide (temo) and of 5FU + streptozotocin (strepto) given with a new schedule (LV5FU2 + strepto), two of the most used chemotherapy regimens in the treatment of well differentiated pancreatic neuroendocrine tumors alone or in combination with bevacizumab (beva) on progression-free survival (PFS) and compare the chemotherapy regimens alone or with beva (two by two design) on the same criteria.
Pancreatic Cancer
DRUG: LV5FU2|DRUG: Streptozocin|DRUG: Capecitabine|DRUG: Temozolomide|DRUG: Bevacizumab
Progression Free Survival (PFS) rate, Until disease progression or unacceptable toxicity (median 24 months)
Toxicity (NCI-CTCAE 4.0), Until disease progression or unacceptable toxicity
Compare the effect of capecitabine (cape) + temozolomide (temo) and of 5FU + streptozotocin (strepto) given with a new schedule (LV5FU2 + strepto), two of the most used chemotherapy regimens in the treatment of well differentiated pancreatic neuroendocrine tumors alone or in combination with bevacizumab (beva) on progression-free survival (PFS) and compare the chemotherapy regimens alone or with beva (two by two design) on the same criteria.